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Background: Anthroposophic medications (AMED) are prescribed in 56 countries.
Objective: To study clinical outcomes in patients prescribed AMED for chronic disease.
Design: Prospective cohort study.
Setting: 110 medical practices in Germany.
Participants: 665 consecutive outpatients aged 1–71 years, prescribed AMED for mental, 
respiratory, musculoskeletal, neurological, genitourinary, and other chronic diseases.
Main outcomes: Disease and Symptom Scores (physicians’ and patients’ assessment, 0–10) 
and SF-36.
Results: During the ﬁ  rst six months, an average of 1.5 AMED per patient was used, in total 
652 different AMED. Origin of AMED was mineral (8.0% of 652 AMED), botanical (39.0%), 
zoological (7.2%), chemically deﬁ  ned (13.0%), and mixed (33.0%). From baseline to six-month-
follow-up, all outcomes improved signiﬁ  cantly: Disease Score improved by mean 3.15 points 
(95% conﬁ  dence interval 2.97–3.34, p  0.001), Symptom Score by 2.43 points (2.23–2.63, 
p  0.001), SF-36 Physical Component Summary by 3.04 points (2.16–3.91, p  0.001), and 
SF-36 Mental Component Summary by 5.75 points (4.59–6.92, p  0.001). All improvements 
were maintained at 12-month follow-up. Improvements were similar in adult men and women, 
in children, and in patients not using adjunctive therapies.
Conclusion: Outpatients using AMED for chronic disease had long-term reduction of disease 
severity and improvement of quality of life.
Keywords: anthroposophy, chronic disease, drug therapy, outcome and process assessment 
(health care), prospective studies, quality of life
Background
In the developed world, the most frequent reason for people to seek health care is a 
chronic disease (Dowrick et al 2005). Chronic diseases are the most common cause 
of disease burden worldwide, are often associated with comorbidity, and are rarely 
completely cured (Dowrick et al 2005). Many patients with chronic disease use 
complementary therapies (Eisenberg et al 1998; Al Windi 2004), sometimes provided 
by their physicians.
One such physician-provided complementary therapy system is anthroposophic 
medicine (AM), founded by Rudolf Steiner and Ita Wegman (Steiner and Weg-
man 2000). AM acknowledges a spiritual – existential dimension in man, which is 
assumed to interact with psychological and somatic levels in health and disease. AM 
therapy for chronic disease aims to counteract constitutional vulnerability, stimulate 
salutogenetic self-healing capacities, and strengthen patient autonomy (Evans and 
Rodger 1992; Ritchie et al 2001; Kienle et al 2006a). This is sought to be achieved by 
counseling (Ritchie et al 2001), by nonverbal artistic therapies such as painting or clay Drug Design, Development and Therapy 2008:2 26
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(Collot d’Herbois 1993; Hauschka-Stavenhagen 1997), music 
(Maurer 1994) or speech exercises (Lorenz-Poschmann 
1982), by eurythmy movement exercises (Kirchner-Bockholt 
1977), by physical therapies (Hauschka-Stavenhagen 1990; 
Ostermann et al 2003), and by special anthroposophic 
medications (AMED). A key concept of AMED therapy is 
typological correspondences between pathophysiological 
processes in man and formative forces working in minerals, 
plants, and animals, reﬂ  ecting a common evolution of man 
and nature (Evans and Rodger 1992; Steiner and Wegman 
2000; Ritchie et al 2001; Kienle et al 2006a). These corre-
spondences go beyond the simile principle of homeopathy 
(a remedy taken in concentrated form induce symptoms 
which are treated by the same remedy taken in homeopathic 
potencies*) and are used therapeutically in medications of 
mineral, botanical or zoological origin, and in chemically 
deﬁ  ned substances. The manufacturing of AMED products 
includes special pharmaceutical processes which are rarely 
used for homeopathic remedies and other non-AMED prod-
ucts: eg, the production of metal mirrors by chemical vapor 
decomposition, and the processing of herbs by fermentation, 
toasting, carbonizing, incineration or digestion (heat treat-
ment at 37 °C). AMED can be prepared in concentrated 
form or in homeopathic potencies, but unlike homeopathy, 
AMED products are rarely prepared in potencies higher 
than D30*. Moreover, AMED products are administered 
in various ways (oral, rectal, vaginal, conjunctival, nasal or 
percutaneous application, or by subcutaneous, intracutane-
ous or intravenous injection). Typically, AMED products in 
concentrated form and oral or rectal administration are used 
to affect pathophysiological processes seen to originate in 
the metabolic system; AMED products in decimal potencies 
up till D12–D15 and AMED administration by injections are 
used to affect rhythmical processes such as respiration and 
circulation; while AMED products in decimal potencies of 
D20–D30 and external applications are used to treat pathol-
ogy originating in the sense-nervous system (Husemann and 
Wolff 1987; Anonymous 2005c). AMED therapy can be stan-
dardized (eg, Ferrum-Quarz Capsules for migraine, Meteoric 
Iron Globuli for fatigue) or individualized (involving one 
or several AMED products and sometimes nonmedication 
AM therapies) (Kienle et al 2006a). A number of standard-
ized AMED therapy regimens can be prescribed by any 
physician, while individualized AMED treatment requires 
special training. Accordingly, in Europe, AMED products are 
prescribed by approximately 30,000 physicians (Anonymous 
2005b), while 2000 certiﬁ  ed AM physicians also provide 
individualized therapy (Anonymous 2005a). Worldwide, AM 
physicians work in 56 countries (Anonymous 2004). Prior 
to prescription of individualized AMED treatment or refer-
ral to other AM therapies, AM physicians have prolonged 
consultations with their patients. These consultations are 
used to take an extended history, to address constitutional, 
psychosocial, and biographic-existential aspect of patients’ 
illness, to explore the patient’s preparedness to engage in 
treatment, and to select optimal therapy for each patient 
(Evans and Rodger 1992; Ritchie et al 2001).
Because of the large number of AMED in use (currently 
more than 2,000 different AMED products are on the market 
[Anonymous 2005b]), clinical studies of single AMED for single 
indications are feasible for only a small proportion of AMED. 
Most such studies conducted up till now concerned mistletoe 
products for cancer (Kienle et al 2006a; Kienle and Kiene 2007). 
Moreover, since AMED therapy for chronic disease is often 
individualized (Kienle et al 2006a), a whole-system evaluation 
approach may be more appropriate than single medication stud-
ies (Fonnebo et al 2007). Here we present a study of AMED 
therapy for chronic diseases, evaluated as a whole system.
Methods
Objective and design
This is a prospective cohort study in a real-world medical 
setting. The study was part of a research project on the 
effectiveness and costs of AM therapies in outpatients with 
chronic disease (Anthroposophic Medicine Outcomes Study, 
AMOS) (Hamre et al 2004, 2006b). The AMOS project was 
initiated by a health insurance company in conjunction with 
a health beneﬁ  t program. The primary research question 
of the present study was: Is physician-prescribed AMED 
therapy for chronic disease associated with clinically relevant 
improvement of disease symptoms? Further research ques-
tions addressed quality of life, use of adjunctive therapies, 
adverse reactions, and therapy satisfaction.
Setting, participants, and therapy
All physicians certiﬁ  ed by the Physicians’ Association for 
Anthroposophical Medicine in Germany and working in 
an ofﬁ  ce-based practice or outpatient clinic were invited to 
participate in the study. Certiﬁ  cation as an AM physician 
required a completed medical degree and a three-year struc-
tured postgraduate training. The participating physicians 
*All homeopathic and many anthroposophic medications are ‘potentized’, 
ie, successively diluted, each dilution step involving a rhythmic succussion 
(repeated shaking of liquids) or trituration (grinding of solids into lactose 
monohydrate). A D30 potency (also called 30X) has been potentized in a 
1:10 dilution for 30 times, resulting in a 1:10−30 dilution.Drug Design, Development and Therapy 2008:2 27
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recruited consecutive patients starting AM therapy. Patients 
enrolled in the period 1 January 1999 to 31 December 2005 
were included in the present analysis if they fulﬁ  lled the eli-
gibility criteria.
The following inclusion criteria were used: (i) Outpa-
tients aged 1–75 years; (ii) AM-related consultation of at 
least 30 minutes or referral to AM therapy (art, eurythmy or 
rhythmical massage) for any indication (main diagnosis); 
(iii) duration of main diagnosis of at least 30 days at study 
enrolment; (iv) new prescription of at least one AMED for 
main diagnosis at study enrolment.
Patients were excluded if they had previously received AM 
(see [ii] of inclusion criteria) for their main diagnosis. Medica-
tions were classiﬁ  ed as AMED products (any medication pro-
duced by Abnoba Arzneimittel GmbH, Pforzheim, Germany; 
Helixor Heilmittel GmbH and Co, Rosenfeld, Germany; 
WALA Heilmittel GmbH, Eckwälden, Germany; or Weleda 
AG, Schwäbisch-Gmünd, Germany) and non-AMED products 
(all other medications). Patients were treated at the physi-
cians’ discretion; physicians were thus free to individualize 
treatment. AMED therapy was evaluated as a whole system, 
including physician-patient interactions. Additional costs for 
AM treatments were 0.1–5.2 Euro per daily dose of an AMED 
(51 different price groups, median 0.2 Euro, mean 0.8 Euro); 
20–32 Euro per AM therapy session; and 46 Euro and 92 Euro 
for AM consultations with physician of 30 min and 60 min 
duration, respectively. These costs were reimbursed by some 
but not all German health insurance companies.
Clinical outcomes
Disease severity
Primary outcome was disease severity at six-month follow-
up. Disease severity was assessed on numerical rating scales 
(Downie et al 1978) from 0 (“not present”) to 10 (“worst 
possible”): Disease Score (physician’s global assessment 
of severity of main diagnosis); Symptom Score (patients’ 
assessment of one to six most relevant symptoms present 
at baseline). Disease Score was documented after 0 and 6 
months, Symptom Score and quality of life outcomes (see 
below) after 0, 3, 6, and 12 months.
Quality of life
In adults (17–75 years) quality of life was assessed with SF-36® 
Health Survey, a widely used self-report measure of functional 
impairment and disability. SF-36 comprises 36 questions 
yielding eleven scores: the SF-36 Physical and Mental 
Component Summary Measures, the eight SF-36 subscales, 
and the SF-36 Health Change item (Bullinger et al 1998).
In children aged 8–16, quality of life was assessed with 
self-report, using the KINDL® Questionnaire for Measuring 
Health-Related Quality of Life in Children and Adolescents, 
Total Quality of Life Score. For patients enrolled up till 
March 2001 the KINDL 40-item version (Ravens-Sieberer 
and Bullinger 1998) was used; for patients enrolled April 
2001 and thereafter the KINDL 24-item version (Ravens-
Sieberer and Bullinger 2000) (Kid-KINDL® for age 8–12, 
Kiddo-KINDL® for age 13–16) was used. The KINDL 
questionnaire addresses physical and emotional well-being, 
self-esteem, family, friends, and everyday functioning.
In children aged 7 years, quality of life was assessed 
by caregivers. For patients enrolled up till March 2001 the 
KITA Quality of  Life Questionnaire (Wittorf 2001) (age 1–7) 
was used. The KITA questionnaire comprises the subscales 
Psychosoma and Daily Life. For patients enrolled April 2001 
and thereafter Kiddy-KINDL®, Total Quality of Life Score 
(Ravens-Sieberer and Bullinger 2000) (age 4–7) was used.
Other outcomes
Patients rated therapy outcome (0–10) and satisfaction with ther-
apy (0–10) after 6 and 12 months. Adverse drug reactions were 
documented by patients after 6 and 12 months, and by physicians 
after 6 months (for patients enrolled before 1 April 2001 also 
after 3, 9, and 12 months). Documentation included suspected 
cause, intensity (mild/moderate/severe = no/some/complete 
impairment of normal daily activities), and therapy withdrawal 
because of adverse reactions. Serious adverse events (death, 
life-threatening condition, acute in-patient hospitalization, new 
disease or accident causing permanent disability, congenital 
anomaly, new malignancy) were documented by physicians.
Data collection
All data were documented with questionnaires sent in sealed 
envelopes to the study ofﬁ  ce. Physicians documented eligi-
bility criteria and medication prescription; all other items 
were documented by patients (by caregivers of children 
17 years) unless otherwise stated. Patient responses were 
not made available to physicians.
Medication use in the preceding 3 (or 6) months was 
documented at each follow-up after 3, 6, and 12 months 
(name, administration frequency [daily, 3–6 days per week, 
1–2 days per week, 1–3 days per month, 1 day per month] 
and duration of use). Physicians were compensated 40 Euro 
per included and fully documented patient; patients received 
no compensation.
Data were entered twice by two different persons into 
Microsoft® Access 97 (Microsoft Corporation, Richmond, Drug Design, Development and Therapy 2008:2 28
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VA, USA). The two datasets were compared and discrepan-
cies resolved by checking with the original data.
Quality assurance, adherence 
to regulations
The study was approved by the Ethics Committee of the 
Faculty of Medicine Charité, Humboldt University, Berlin, 
Germany, and was conducted according to the Declaration of 
Helsinki and the International Conference on Harmonisation 
Good Clinical Practice guidelines. Written informed consent 
was obtained from all patients before enrolment.
Data analysis
Data analysis (SPSS® 14.0.1, SPSS Inc., Chicago, Ill, USA; 
StatXact® 5.0.3, Cytel Software Corporation, Cambridge, 
MA, USA) was performed on all patients fulﬁ  lling eligibility 
criteria for this study. For continuous data t-test was used. For 
binominal data McNemar test and Fisher’s exact test were 
used. All tests were two-tailed. Signiﬁ  cance criteria were 
p  0.05 and 95% conﬁ  dence interval (95% CI) not includ-
ing 0. Since this was a descriptive study, no adjustment for 
multiple comparisons was performed (Feise 2002). Pre-post 
effect sizes were calculated as Standardized Response Mean 
(= mean change score divided by the standard deviation of the 
change score) and classiﬁ  ed as small (0.20–0.49), medium 
(0.50–0.79), and large (0.80) (Liang et al 1990).
For analysis of medication use, missing data on adminis-
tration frequency were replaced by the value 3/7 (three times 
weekly) for AMED ampoules for injection, and 1 (daily) for 
all other medications; missing data on duration of AMED or 
non-AMED use were replaced by average duration of AMED 
and non-AMED use, respectively, during the follow-up period 
in question. AMED with identical ingredients and dosage form 
but different concentrations were grouped together. For each 
medication, the number of patient-months was calculated as 
‘duration of use’ × F (where F = 1 for medication taken daily, 
3–6 days per week or 1–2 days per week; F = 1/15 for medi-
cation taken 1–3 days per month; F = 0 for medication taken 
1 day per month). The number of patient-months for all 
AMED, all non-AMED, and for relevant medication subgroups 
was calculated as the sum of all patient-months in question. 
Clinical outcomes were analyzed in patients with evaluable data 
for each follow-up, without replacement of missing values.
Five pre-planned sensitivity analyses (SA1-SA5) were 
performed to assess the inﬂ  uence of patient attrition, natural 
recovery, adjunctive nonmedication AM therapies, and 
adjunctive diagnosis-relevant non-AM therapies on the 
0–6-month Disease Score outcome. SA1 was a preparatory 
analysis, necessary to perform two subsequent analyses (SA3 
and SA5, see below) and was retained in all subsequent analyses: 
The sample was restricted to patients with six-month-patient-
follow-up questionnaire available. SA2 concerned attrition 
bias: Missing values after six months were replaced with 
the baseline value carried forward. SA3 concerned the effect 
of adjunctive AM therapies (eurythmy, art, and rhythmical 
massage therapy): The sample was restricted to patients using 
no such therapy in the ﬁ  rst six study months. SA4 concerned 
natural recovery, which was assumed to be unlikely in AMOS 
patients with disease duration of at least one year (Hamre et al 
2007a). The sample was restricted to patients with disease 
duration of at least 12 months prior to study enrolment. SA5 
concerned the effects of relevant non-AM adjunctive therapies, 
and was performed on patients with a main diagnosis of mental, 
respiratory or musculoskeletal diseases, headache syndromes 
or menstruation-related gynecological disorders. In SA5, this 
sample was restricted to patients not using diagnosis-related 
adjunctive therapies during the ﬁ  rst six study months.
Results
Participating physicians
A total of 110 physicians enrolled patients into the study; 
these physicians did not differ significantly from AM-
certified physicians in Germany not enrolling patients 
(n = 286) regarding age (mean ± SD: 47.1 ± 7.1 vs 48.8 ± 8.3 
years), number of years in practice (18.4 ± 7.7 vs 19.6 ± 9.2 
years) or the proportion of primary care physicians (82.7% 
vs 85.9%). The percentage of men was higher in AM physi-
cians enrolling patients (50.9%) than in AM physicians not 
enrolling patients (33.9%) (p = 0.003).
Patient recruitment and follow-up
From 1 January 1999 to 31 December 2005, a total of 1,905 
patients were assessed for eligibility. Of these patients, 
665 fulﬁ  lled all eligibility criteria and were included in the 
analysis. Of the 1,240 patients who were not included, 831 
were not eligible for the present analysis, for the following 
reasons: no AMED prescription for main diagnosis at study 
enrolment (n = 715), disease duration 30 days (n = 45), 
age 1 year or 75 years (n = 19), previous participation 
in the AMOS study (n = 21), previous or ongoing use of AM 
therapy in question (n = 31). The remaining 409 patients were 
potentially eligible but not evaluable for the present analysis 
because of missing data for medication prescription at study 
enrolment (n = 118) or were not included in the AMOS study 
for the following reasons: patients’ baseline questionnaire 
missing (n = 137), physicians’ baseline questionnaire missing Drug Design, Development and Therapy 2008:2 29
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(n = 40), patients’ and physicians’ baseline questionnaire 
dated 30 days apart (n = 78), no informed consent (n = 13), 
other reasons (n = 23).
The not-included, potentially eligible patients (NIPE, 
n = 409) did not differ signiﬁ  cantly from included patients 
(n = 665) regarding age, gender, disease duration, baseline Dis-
ease Score or baseline Symptom Score. A main diagnosis of a 
mental disorder (International Classiﬁ  cation of Diseases, Tenth 
Edition [ICD-10] F00-F99) was more frequent in NIPE patients 
(43.1%) than in included patients (30.1%) (p  0.001).
A total of 66.9% (445 of 665) of patients were enrolled 
by general practitioners, 12.8% by pediatricians, 9.0% by 
internists, and 11.3% by other specialists. The physicians’ 
settings were primary care practices (75.0% of patients, 
n = 499 of 665), referral practices (16.5%), and outpatient 
clinics (8.4%). Each physician enrolled 1–4 patients (68%, 
75/110 physicians), 5–9 patients (15%) or 10 patients 
(16%), with a median of 3.0 patients per physician (range 
1–45 patients, interquartile range [IQR] 1.0–6.0 patients). 
The last patient follow-up ensued on 5 February 2007.
A total of 93.4% (621/665) of patients returned at least 
one follow-up questionnaire. Follow-up rates were 90.5% 
(602 of 665), 84.7%, and 81.5% after 3, 6, and 12 months, 
respectively. Respondents and non-respondents of the six-
month patient-follow-up did not differ signiﬁ  cantly regarding 
age, gender, diagnosis, disease duration, baseline Disease 
Score or baseline Symptom Score. The physician six-month 
follow-up documentation was available for 92.0% (612/665) 
of patients.
Baseline characteristics
Disease status
Most main diagnoses belonged to the following ICD-10 
chapters: F00-F99 Mental Disorders (30.1%, 200 of 665 
patients), J00-J99 Respiratory Diseases (14.7%), M00-M99 
Musculoskeletal Diseases (11.1%), G00-G99 Nervous Sys-
tem Diseases (8.0%), and N00-N99 Genitourinary Diseases 
(7.1%). Most common diagnosis subgroups were Asthma/
Sinusitis/Bronchitis (J32, J40-J42, J44-J45: 11.1%, 74 of 
665 patients), Mood Disorders (F31-F39: 9.8%), Headache 
(G43-G44, R51: 5.3%), and Menstruation-related Gyneco-
logical Disorders (N80, N92, N94.3-N94.6, N95: 4.7%). 
The disease duration was 1–2 months in 5.4% (36/662) of 
evaluable patients, 3–5 months in 5.9%, 6–11 months in 
9.0%, and 12 months in 79.6%, with a median disease 
duration of 3.3 (IQR 1.0–10.0) years. Patients had a median 
of 1.0 (IQR 1.0–2.0) comorbid diseases. The most common 
comorbid diseases were M00-M99 Musculoskeletal Diseases 
(14.3%, 145 of 1,015 diagnoses), F00-F99 Mental Disorders 
(11.8%), J00-J99 Respiratory Diseases (11.1%), and 100–199 
Cardiovascular Diseases (8.8%).
Socio-demographic data
Patients were recruited from 15 of 16 German federal states. 
Age groups were 1–19 years (29.9%, 199 of 665 patients), 
20–39 years (25.3%), 40–59 years (34.9%), and 60–75 years 
(9.9%) with a median age of 37.0 years (IQR 12.9–47.5 
years, mean 33.9 years, SD 19.3). A total of 68.4% (455 
of 665) of patients and 79.7% (379/475) of adults were 
women. Compared with the German population, patients 
had higher educational and occupational levels and were 
less frequently unemployed, living alone, regular smokers, 
daily alcohol consumers, and overweight; socio-demographic 
status was similar to the population regarding low income 
and less favorable for work disability pension and sick-leave 
(Table 1).
Therapy in the ﬁ  rst six study months
At study enrolment, the duration of the consultation with the 
AM physician was 30 min in 22.1% (147/665) of patients, 
30–44 min in 30.4%, 45–59 min in 15.5%, and 60 min in 
20.3% of patients. During the ﬁ  rst six study months, use of 
at least one AMED product was documented for 77.6% (443 
of 571) of evaluable patients. Administration frequency for 
AMED was daily (73.4%, 1,239 of 1,689 documentations), 
3–6 days per week (8.8%), 1–2 days per week (12.1%), 1–3 
days per month (2.7%), 1 day per month (0.7%), unknown 
(2.3%). A total of 3,930 patient-months of AMED use were 
documented, corresponding to a continuous use of average 
1.5 AMED per patient during the six-month period. Six-
hundred and ﬁ  fty-two (652) different AMED were used; 
the origin of AMED was mineral (8.0%, 52 of 652 AMED), 
botanical (39.0%), zoological (7.2%), chemically deﬁ  ned 
(13.0%), and mixed (33.0%). The most common administra-
tion forms were dilutions for oral use (31.4%, 205 of 652 
AMED), ampoules for injection (20.1%), globuli (19.8%), 
powders (10.9%), and ointments (6.9%). The most frequently 
used individual AMED products were Hepatodoron Tablets 
(used by 8.4%, 37 of 443 evaluable patients), Cardiodoron 
Liquid (4.5%), Abnobaviscum Ampoules (3.6%), Phospho-
rous Liquid (3.4%), and Ovaria comp. Globuli (2.9%).
Non-AMED products were used by 69.0% (388 of 562) of 
evaluable patients. In total 3,295 patient-months of non-AMED 
use were documented; the most frequently used Anatomical 
Therapeutic Chemical Classiﬁ  cation Index groups were Ner-
vous System (18.9%, 623 of  3,295 patient-months), Alimentary Drug Design, Development and Therapy 2008:2 30
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Tract and Metabolism (14.1%), Respiratory System (10.0%), 
and Cardiovascular System (9.7%). AM adjunctive therapies 
(eurythmy, art or rhythmical massage therapy) were used by 
50.0% (280 of 559) of evaluable patients.
Use of diagnosis-related non-AM adjunctive therapies 
within the ﬁ  rst six study months was analyzed in patients 
with a main diagnosis of mental, respiratory or musculosk-
eletal diseases, headache syndromes or menstruation-related 
gynecological disorders (Table 2, n = 438). Patients were 
classiﬁ  ed as users if they had used at least one of the listed 
therapies for at least one day per month. Out of 356 evaluable 
patients, 64.9% (n = 231) had no diagnosis-related adjunc-
tive therapy.
Clinical outcomes
Disease severity
Disease and Symptom Scores (Figure 1) improved signiﬁ  -
cantly and progressively between baseline and all subsequent 
follow-ups. After six months, an improvement of 30% of 
baseline scores was observed in 67.4% (393 of 583 evaluable 
patients) and 59.7% (334/559) for Disease and Symptom 
Scores, respectively; an improvement of  50% was observed 
in 50.0% (292/583) and 43.5% (243/559), respectively. 
Standardized Response Mean effect sizes for the 0–6 month 
comparison were large for both scores (Table 3).
Disease and Symptom Scores were analyzed in adult 
men and women, in children, and in the nine diagnostic sub-
groups listed in the ‘Baseline characteristics’ section. From 
baseline to six-month follow-up, both outcomes improved 
signiﬁ  cantly in all analyzed subgroups (p = 0.002 for Disease 
Score in Malignancies; p  0.001 for all other comparisons). 
With one exception (Symptom Score in Menstruation-related 
Gynecological Disorders: effect size 0.76), all effect sizes 
were large. Among the ﬁ  ve most common ICD-10 chapters, 
effect sizes for Disease Score ranged from 1.10 (M00–M99 
Musculoskeletal Disease) to 1.61 (G00–G99 Nervous System 
Diseases), while effect sizes for Symptom Score ranged from 
0.85 (N00–N99 Genitourinary Diseases) to 1.15 (J00–J99 
Respiratory Diseases). The 0–6 month improvements of 
Disease and Symptom Score did not correlate with education 
level (Spearman Rho for Disease Score r = −0.04, p = 0.411; 
for Symptom Score r = 0.06, p = 0.212) or duration of consul-
tation at study enrolment (Disease Score r = 0.04, p = 0.505; 
Symptom Score r = 0.00, p = 0.995).
We performed ﬁ  ve sensitivity analyses of 0–6 month 
Disease Score outcomes (Table 4: SA1-SA5; see Methods 
for further description). The individual analyses had only 
small effects, reducing the improvement by maximum 10%. 
Combining all ﬁ  ve analyses, Disease Score improvement was 
reduced by 15% (3.27→2.78 points).
Table 1 Socio-demographic characteristics of adult study patients
Item Subgroup  Patients    German  population
   N  %  %  Reference
Education (Brauns and Steinmann 1997)          (Federal Statistical Ofﬁ  ce 2001)
-Low (grade 1)    83/475  17%  43%  (Anonymous 2000)
-Intermediate (grade 2)    242/475  51%  43% 
-High (grade 3)    150475  32%  14% 
Wage earners    19/475  4%  18%  (Federal Statistical Ofﬁ  ce 2001)
Unemployed during last 12 months  Economically  15/277  5%  10%  (Federal Statistical Ofﬁ  ce 2001)
 active  patients
Living alone     91/661  14%  21%  (Federal Statistical Ofﬁ  ce 2001)
Net family income 900   per month    64/388  16%  16%  (Federal Statistical Ofﬁ  ce 2001)
Alcohol use daily (patients) vs almost  Male  9/96  9%  28%  (Hoffmeister et al 1999)
daily (Germany)  Female  5/379  1%  11% 
Regular smoking  Male  12/96  13%  37%  (Junge and Nagel 1999)
 Female  38/378  10%  28% 
Sports activity 1 hour weekly   Age 25–69  206/432  48%  39%  (Breckenkamp et al 2001)
Body mass index 18.5 (low)  Male  0/94  0%  1%  (Federal Statistical Ofﬁ  ce 2001)
 Female  26/373  7%  4% 
Body mass index 25 (overweight)  Male  34/94  36%  56%  (Federal Statistical Ofﬁ  ce 2001)
 Female  93/373  25%  39% 
Permanent work disability pension    39/475  8%  3%  (Association of German Pension
          Insurance Companies 2005)
Severe disability status    47/475  10%  12%  (Bergmann and Ellert 2000)
Sick leave days in the last 12 months  Economically  34.2    17.0  (Anonymous 2003)
(mean) active  patientsDrug Design, Development and Therapy 2008:2 31
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Quality of life
In adults, all eleven SF-36 scores (Figure 2) improved 
signiﬁ  cantly and progressively between baseline and all 
subsequent follow-ups (one exception to progressive 
improvement: SF-36 Health Change score was unchanged 
from 6-month to 12-month follow-up). In children, quality 
of life scores improved progressively between baseline and 
most subsequent follow-ups (improvement at 12 out of 
15 follow-ups); seven of 15 improvements were statistically 
signiﬁ  cant. Effect sizes for the 0–6 month comparison were 
medium for ﬁ  ve quality of life scores and small for 11 scores 
(Table 3).
Other outcomes
At six-month follow-up, patients’ average therapy outcome 
rating (numeric scale from 0 “no help at all” to 10 “helped 
Table 2 Diagnosis-related adjunctive therapies
Main diagnosis (International classiﬁ  cation  Drugs (Anatomical therapeutic chemical    Non-medication 
of diseases, tenth edition)  classiﬁ  cation index)  therapy
Mental disorders (F00-F99)  Antiepileptic, psycholeptic, analeptic, and anti-addiction   Psychotherapy (in 
  drugs (N03A, N05-06, N07B)  children ergotherapy
    or play therapy)
Respiratory disorders (J00-J99)  Respiratory drugs (H02, J01-02, J04-05, J07A, L03, R01,   Relevant surgery
 R03,  R06-07) 
Musculoskeletal diseases (M00-M99)  Immunosuppressive, musculoskeletal, analgesic, and   Physiotherapy, 
  antidepressant drugs (L04, M01-05, M09, N02A-B, N06A)  relevant surgery
Headache disorders (G43-G44, R51)  Analgesics, antimigraine drugs, antidepressants (C04AX01,  
  C07AA05, C07AB02, C08CA06, C08DA01, N02,  
  N03AG01, N06A, N07CA03) 
Menstruation-related gynecological disorders   
-Endometriosis (N80)  Sex hormones, gonadotropin-releasing hormone analogues   Relevant surgery
 (G03,  L02AE)   
-Excessive, frequent and irregular menstruation (N92)  Sex hormones, iron preparations (G03, B03A)  Relevant surgery
-Premenstrual tension syndrome (N94.3)  Sex hormones, antidepressants, diuretics (G03, N06A, C03) 
-Dysmenorrhea (N94.4-94.6)  Sex hormones, analgesics, non-steroid anti-inﬂ  ammatory  
  drugs, muscle relaxants (G03, N02, M01A-M01B, M03) 
-Menopausal and other perimenopausal disorders (N95) Sex  hormones  (G03)
Figure 1 Disease Score (physicians’ assessment), Symptom Score (patients’ assessment), 0 “not present”, 10 “worst possible”.
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Anthroposophic medications
very well”) was 7.12 ± 2.46; patient satisfaction with therapy 
(from 0 “very dissatisfied” to 10 “very satisfied”) was 
7.80 ± 2.26. Ratings of therapy outcome and satisfaction 
did not differ signiﬁ  cantly between adults (patient rating) 
and children (proxy rating by caregivers). From 6- to 12-
month follow-up, patient satisfaction decreased by average 
0.24 points, 95% CI 0.03–0.45, p = 0.024, whereas patients’ 
therapy outcome rating did not change signiﬁ  cantly.
Adverse drug reactions were reported signiﬁ  cantly less 
frequently from AMED than from non-AMED products 
(Table 5).
Serious adverse events were documented in 12 patients. 
Six patients died from a malignant disease (cervical carcinoma 
in two patients, four different malignancies in remaining 
four patients) that had been present at study enrolment. One 
patient suffered a whiplash injury with permanent disability. 
Table 4 Disease Score 0–6 months: Sensitivity analysis (SA)
Item  N  0 months  6 months  0–6 month difference
   Mean  ±SD Mean  ±SD Mean  (95%-CI)  p-value
Main analysis: patients with evaluable Disease   583  6.71  ±1.86 3.56  ±2.29 3.15  (2.97–3.34) p   0.001
Score at 0 and 6 months              
SA1: Patients with 6-month patient-follow-up   503  6.71  ±1.88 3.58  ±2.28 3.14  (2.93–3.34) p   0.001
questionnaire available             
SA2: Baseline value carried forward  560  6.69  ±1.87 3.87  ±2.39 2.82  (2.62–3.02) p   0.001
SA3: Patients not using eurythmy or art therapy   250  6.39  ±1.95 3.17  ±2.12 3.22  (2.93–3.51) p   0.001
or rhythmical massage therapy in month 0–6              
SA4: Patients with disease duration 12 months   401  6.81  ±1.86 3.74  ±2.29 3.06  (2.83–3.29) p   0.001
at study enrolment              
SA1 + SA2 + SA3 +  SA4  220  6.52  ±1.91 3.70  ±2.34 2.83  (2.50–3.15) p   0.001
Patients with main diagnosis of musculoskeletal or mental              
diseases, headache disorders, or menstruation-related              
gynecological disorders             
Main analysis: patients with evaluable Disease  392  6.66  ±1.78 3.39  ±2.18 3.27  (3.04–3.49) p   0.001
Score at 0 and 6 months             
SA 1: Patients with 6-month patient-follow-up   331  6.66  ±1.79 3.45  ±2.17 3.20  (2.96–3.44) p   0.001
questionnaire available             
SA5: Patients not using diagnosis-related adjunctive  208  6.54  ±1.82 3.24  ±2.16 3.30  (2.98–3.62) p   0.001
therapies (see text) in month 0–6              
SA1 + SA2 + SA3 + SA4 + SA5  94  5.98  ±1.82 3.20  ±2.19 2.78  (2.32–3.23) p   0.001
Figure 2 SF-36 Physical and Mental Component Summary Measures. Higher scores indicate better health. Adult patients.
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Five patients were acutely hospitalized: two patients for 
exacerbation of paranoid schizophrenia; remaining three 
patients for thrombosis of lower extremity, intestinal 
perforation from swallowing ﬁ  sh bones, and life-threatening 
adhesive ileus, respectively. The patients with thrombosis 
and ileus had sequelae; the other acutely hospitalized patients 
recovered completely. None of these serious adverse events 
were causally related to any medication or therapy.
Discussion
This prospective cohort study is the ﬁ  rst study of individual-
ized AMED therapy for chronic disease performed in ofﬁ  ce-
based settings. We aimed to obtain information on AMED 
therapy under routine conditions in Germany and studied 
clinical outcomes in outpatients with a new prescription 
of AMED for chronic diseases. Most frequent indications 
were mental, respiratory, musculoskeletal, neurological, and 
genitourinary disorders.
Following AMED therapy, signiﬁ  cant improvements of 
disease symptoms and quality of life were observed.
Strengths of this study include a long follow-up period, 
high follow-up rates for the physician documentation, and 
the participation of 28% of all AM-certiﬁ  ed physicians in 
Germany. The participating physicians resembled eligible but 
not participating physicians with respect to demographic char-
acteristics, and the included patients resembled not included, 
potentially eligible patients regarding baseline characteristics. 
These features suggest that the study to a high degree mirrors 
contemporary AMED therapy in outpatient settings.
On the other hand, it was not feasible to have disease-
speciﬁ  c outcomes for all diagnoses included. Nonetheless, 
the larger AMOS project, of which this study is part, included 
disease-speciﬁ  c outcomes for major disease groups (Hamre 
et al 2006a, 2007b).
Since the study had a long recruitment period, the study 
physicians were not able to participate throughout the period 
and to screen and enroll all eligible patients (criteria: see 
Methods section). For patients referred to AM therapies and 
enrolled before 1 April 2001, it was estimated that physicians 
enrolled every fourth eligible patient (Hamre et al 2006a). This 
selection could bias results if physicians were able to predict 
therapy response and if they preferentially screened and enrolled 
such patients for whom they expected a particularly favorable 
outcome. In this case one would expect the degree of selection 
(= the proportion of eligible vs enrolled patients) to correlate 
positively with clinical outcomes. That was not the case, the 
correlation was almost zero (−0.04). This analysis (Hamre et al 
2006a) does not suggest that physicians’ screening of eligible 
patients was affected by selection bias. – Among screened 
patients who were potentially eligible, 38% could not be 
included in the analysis (NIPE-patients), mostly because of 
missing baseline data. NIPE patients did not differ from included 
patients regarding demographics, disease severity or disease 
duration, but a main diagnosis of mental disorders was more 
frequent among NIPE patients (43% vs 30%), so a selection bias 
affecting the diagnosis distribution cannot be ruled out.
Since 18 clinical outcomes were analyzed, the issue of 
multiple hypothesis-testing arises (Feise 2002). However, 15 
of 18 analyzed 0–6 month comparisons of clinical outcomes 
showed signiﬁ  cant improvements, with p  0.001 for 13 
outcomes (Table 3).
A limitation of the study is the absence of a comparison 
group receiving another treatment or no therapy. Accord-
ingly, for the observed improvements one has to consider 
several other causes apart from AMED. In a sensitivity 
analysis of Disease Score, attrition bias, adjunctive therapies, 
and natural recovery could together explain only up to 15% 
of the improvement. According to an analysis published 
elsewhere (Hamre et al 2007a), regression to the mean due 
to symptom ﬂ  uctuation with preferential self-selection to 
therapy and study inclusion at symptom peaks could explain 
additionally 0.43 points of the Disease Score improvement, 
resulting in a minimum unexplained improvement of aver-
age 2.35 points (lower boundary of 95% CI 1.89 points). 
Other possible confounders are psychological factors like 
patient expectations. Since, however, AMED therapy was 
evaluated as a whole system, the question of speciﬁ  c therapy 
effects vs nonspeciﬁ  c effects (placebo effects, context effects, 
Table 5 Adverse drug reactions reported from anthroposophic (AMED) and other (non-AMED) medications during the 12-month 
follow-up
 AMED  Non-AMED
 n  = 478 users  n = 465 users
Adverse drug reaction  N  %  N  %  p-value
-any 25  5.2%  42  9.0%  p  = 0.031
-of severe intensity  6  1.3%  15  3.2%  p = 0.047
-leading to discontinuation of medication use  14  2.9%  22  4.7%  p = 0.175Drug Design, Development and Therapy 2008:2 35
Anthroposophic medications
physician-patient interactions, patient expectations etc) was 
not an issue of the present analysis.
Since patients were treated by AM physicians who could 
possibly have an interest in AMED therapy having favorable 
outcomes, study data were largely collected by patients and 
not physicians. Any bias affecting physician’s documenta-
tion would not affect Symptom Score or quality of life, since 
these clinical outcomes were documented by the patients or 
caregivers.
Medication and therapy use was documented by the 
patients at each follow-up and patients may have forgotten 
some medications and therapies, leading to an underesti-
mation of true use (Evans and Crawford 1999). Therefore, 
the proportion of patients using AMED – or using adjunc-
tive therapies (sensitivity analyses SA3 and SA5) – might 
be higher than documented. Since SA3 and SA5 did not 
decrease the Disease Score improvement, a higher propor-
tion of adjunctive therapy users would not be expected to 
reverse these results and would thus not threaten the validity 
of these analyses.
This study confirms previous studies of AM users 
(Ritchie et al 2001; Pampallona et al 2002; Hamre et al 2005; 
Unkelbach and Abholz 2006): Patients are predominantly 
women or children; education and occupation levels are 
higher than average, and typical indications are mental, 
respiratory, and musculoskeletal disorders. Up till now 
AMED therapy for chronic noncancer indications has been 
evaluated in 52 studies. 51 studies showed some beneﬁ  t; 
one study found no benefit (Kienle et al 2006a). Most 
studies concerned single AMED products (29 studies) or 
a ﬁ  xed AMED combination (16 studies). Seven studies 
evaluated individualized AMED therapy in combination with 
nonmedication AM therapies for epilepsy (Madeleyn 1990), 
sciatica (Kienle et al 2006c), atopic diseases (Knol 1989; 
Kienle et al 2006b), anorexia nervosa (Schmitz 1989; Kienle 
et al 2006d), and inﬂ  ammatory rheumatic disorders (Simon 
et al 1997), respectively. These studies were performed in 
inpatient hospitals (Knol 1989; Schmitz 1989; Kienle et al 
2006c, 2006d) or outpatient clinics (Madeleyn 1990; Simon 
et al 1997; Kienle et al 2006b).
In accordance with these studies from secondary care, 
our study from a predominantly primary care setting showed 
signiﬁ  cant improvements of mental, respiratory, musculo-
skeletal, neurological, genitourinary and other chronic dis-
eases following individualized AMED therapy. The largest 
improvements (large effect sizes, half of patients improved 
by at least 50% of their baseline scores) were observed for 
the items which directly measure the conditions treated with 
AMED products, ie, Disease and Symptom Scores. Quality 
of life improvements were less outspoken and not signiﬁ  cant 
in some of the smaller subgroups analyzed (KINDL, KITA 
in children). However, a comparative analysis of a larger 
dataset from the AMOS study shows that quality of life 
improvements in adults (SF-36) are a largely of the same 
order of magnitude as corresponding improvements fol-
lowing other treatments for the same diseases (Hamre et al 
manuscript submitted).
Conclusion
In this study, outpatients using AMED for mental, respi-
ratory, musculoskeletal, neurological, genitourinary, and 
other chronic diseases had long-term reduction of disease 
severity and improvement of quality of life. Improvements 
were similar in patients not using adjunctive therapies and 
in patients with long disease duration. Although the pre-post 
design of the present study does not allow for conclusions 
about comparative effectiveness, study ﬁ  ndings suggest that 
AMED may play a beneﬁ  cial role in the long-term care of 
patients with chronic diseases.
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